Did you mean 2019 10 0?
Displaying drugs 2051 - 2075 of 3452 in total
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
LX-1004
Investigational
CAN-106
CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
Investigational
AVB-101
AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.
Investigational
Apc001PE
Investigational
Silatecan
Silatecan has been used in trials studying the treatment of GBM, Tumors, Gliosarcoma, Solid Malignancies, and Glioblastoma Multiforme, among others.
Investigational
Matched Iupac: … }.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione ... (19S)-10-(tert-butyldimethylsilyl)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11 …
MORAb-066
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Nanaomycin D
Experimental
Matched Iupac: … (11R,15S,17S)-4-hydroxy-17-methyl-12,16-dioxatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-1(10),3(8), …
Intoplicine
Intoplicine has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Iupac: … -1(10),2,4,6,8,12(17),13,15-octaen-5-ol ... 16-{[3-(dimethylamino)propyl]amino}-13-methyl-11,15-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca …
Borocaptate
Investigational
Matched Iupac: … {1,4}.0^{2,6}.0^{2,7}.0^{2,12}.0^{3,5}.0^{3,6}.0^{4,9}.0^{4,11}.0^{5,8}.0^{5,9}.0^{6,8}.0^{7,10}.0^{8,10 ... }.0^{9,11}.0^{10,12}.0^{11,12}]dodecaborane-12-thiol ... 1lambda5,2lambda5,3lambda5,4lambda5,5lambda5,6lambda5,7lambda5,8lambda5,9lambda5,10lambda5,11lambda5,12lambda6-nonadecacyclo[5.4.1.0^{1,3}.0^ …
VAD-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
BMN-046
Experimental
Withdrawn
BMN-055
Experimental
Withdrawn
Becatecarin
Becatecarin is a derivative of rebeccamycin.
Investigational
Matched Iupac: … {4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaene-12,14-dione ... ,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^ …
MP-0250
Investigational
Dalotuzumab
Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Investigational
Wortmannin
Wortmannin is a steroid metabolite of Penicillium funiculosum and Talaromyces wortmannii fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).
Experimental
Matched Iupac: … {5,9}.0^{15,19}]nonadeca-2(10),12(19),14-trien-3-yl acetate ... ,3R,5S,9R,18S)-18-(methoxymethyl)-1,5-dimethyl-6,11,16-trioxo-13,17-dioxapentacyclo[10.6.1.0^{2,10}.0^ …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
BL-1020
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Investigational
ATX-101
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
NOX-100
NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple...
Investigational
VIT-100
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
Displaying drugs 2051 - 2075 of 3452 in total